argenx commenced a tender offer to acquire Forte Biosciences, the clinical-stage developer advancing FB102, a proprietary anti-CD122 monoclonal antibody. The transaction marks argenx's expansion beyond its Fc receptor platform into IL-2 pathway modulation, a mechanism with applications across autoimmune and inflammatory indications where current therapies show incomplete efficacy.
Forte Biosciences entered clinical development with FB102 targeting CD122, the beta subunit of the IL-2 receptor complex expressed on effector T cells and NK cells. The asset completed Phase 1 safety studies and moved into mid-stage trials for atopic dermatitis and alopecia areata. argenx, which built $2.1 billion in 2025 revenue on VYVGART for myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, has been methodical in acquiring late-preclinical and early-clinical assets that address shared immunological targets without cannibalizing existing indication pathways. The tender structure suggests argenx valued Forte's IP estate and clinical data package over any near-term commercial timeline.
The acquisition extends argenx's therapeutic reach into dermatology and autoimmune hair loss, indications where payer familiarity with monoclonal antibodies has improved but competitive pressure from Sanofi, Regeneron, and Eli Lilly remains concentrated in IL-4, IL-13, and JAK pathways. CD122 inhibition offers a differentiated mechanism, potentially allowing argenx to avoid head-to-head comparisons in crowded categories while retaining access to specialist prescriber networks already adopting VYVGART in neuromuscular disease. The FDA granted Forte orphan designation for alopecia areata in 2022, which carries seven years of market exclusivity if FB102 reaches approval. For argenx, this represents a hedge against VYVGART biosimilar erosion expected after 2030 and a second commercial franchise outside neurology.
Allocators should monitor the tender close date and any SEC filings revealing per-share consideration or equity rollovers for Forte management. argenx typically structures these deals with modest upfront cash and milestone-based payouts tied to Phase 2 readouts, preserving balance sheet optionality while aligning seller incentives. Clinical trial databases should reflect updated sponsor listings for FB102 studies within 60 days, signaling integration speed. Any pivot in trial design or endpoint selection will indicate whether argenx views FB102 as a standalone asset or a combination candidate with VYVGART in overlapping autoimmune settings.
The tender opened without a competing bid, which is consistent with Forte's $47 million market capitalization at last close and the limited pool of acquirers with both autoimmune franchises and capital for clinical-stage antibodies.